[Clinical evaluation of MD-805].
T
T
Matsuo
D000368:Aged; D000991:Antithrombins / Q000627:therapeutic use*; D001120:Arginine / Q000031:analogs & derivatives; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D005344:Fibrinopeptide A / Q000378:metabolism; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010875:Pipecolic Acids / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D006435:Renal Dialysis; D013449:Sulfonamides; D013921:Thrombocytopenia / Q000188:drug therapy; D013927:Thrombosis / Q000188:drug therapy*
D000991:Antithrombins; D010875:Pipecolic Acids; D010975:Platelet Aggregation Inhibitors; D013449:Sulfonamides; D005344:Fibrinopeptide A; D006493:Heparin; D001120:Arginine; C031942:argatroban